###### Strengths and limitations of this study

-   First prospective study to assess the impact of particulate matter on mothers and babies in Antwerp, Belgium.

-   Large questionnaires to minimalise bias from multiple factors.

-   Only eligible for Dutch speaking women, which gives a bias.

Introduction {#s1}
============

An emerging body of evidence indicates that there is an association between air pollution exposure in pregnancy and adverse pregnancy outcomes.[@R1] Most studies have estimated personal exposure to air pollution by modelling data from outdoor monitoring stations and interpolating them to the home address of the study participants. The exposure data are averaged over different time periods and in general time spent in traffic or exposure at the workplace or indoors are not taken into account.

Particulate matter (PM) is an important component of outdoor air pollution. PM has different sizes, but especially fine PM, with an aerodynamic diameter less than 2.5 µm (PM~2.5~) is of great interest, because of its small size, large specific surface area and long residence in air, and thus is more likely to adsorb harmful substances. PM~2.5~ consists of a mixture of solid and liquid particles, emitted from a variety of sources. Because of its size it can penetrate in airways until the alveoli from where the particles or the absorbed pollutants may be translocated into the bloodstream.[@R3]

A significant positive association between exposure to fine PM during the third trimester and pre-eclampsia has been observed in a study by Dadvand *et al* among over 8000 pregnant women in Barcelona, Spain.[@R2]

Exposure to local traffic-generated air pollution during pregnancy is also known to increase the risk of pre-eclampsia and preterm birth.[@R4] Proximity to major roads is associated with an increased risk of pre-eclampsia, but not with a higher risk of gestational diabetes, placental abruption or placenta praevia.[@R5]

Hypertensive disorders of pregnancy affect about 10% of all pregnant women. They are an important cause of severe morbidity and even mortality.[@R6] Pre-eclampsia complicates 2%--8% of pregnancies and is a major contributor to maternal and neonatal mortality worldwide.[@R7]

Pre-eclampsia is generally defined as de novo hypertension occurring after 20 weeks of pregnancy (with systolic blood pressure ≥140 mm Hg and/or diastolic blood pressure ≥90 mm Hg) and proteinuria (≥300 mg in 24 hours).[@R6]

The cause of pre-eclampsia still remains largely unknown, but a disturbed placental function early in pregnancy has been suggested as a specific underlying mechanism. In normal pregnancy the uteroplacental arteries undergo a series of pregnancy-related changes in the first 20 weeks. Invasive trophoblasts replace endothelial cells and smooth muscle cells in the media, causing the arteries to lose elasticity and to dilate to wide tubes, without the ability to contract effectively. They also lose their vasomotor control. This mechanism occurs in order to guarantee maternal blood supply to the placenta: the loss of maternal blood flow resistance and the increase of uteroplacental perfusion meet the requirements of the fetus.[@R9] In addition, circulating antiangiogenic factors may play a role in the pathogenesis. The transmembrane protein vascular endothelial growth factor (VEGF) receptor fms-like tyrosine kinase 1 (Flt-1) binds with high affinity to VEGF and to placental growth factor (PlGF).[@R10] Flt-1 is involved in normal angiogenesis. Soluble Flt-1 (sFlt-1) is a variant of Flt-1 that lacks a transmembrane protein, and is a naturally occurring antagonist of VEGF and PlGF. Production of sFlt-1 appears to be expressed by endothelial cells and trophoblasts in response to reduced oxygen tensions.[@R11] In developing pre-eclamptic placenta the normal process of remodelling of the uterine spiral arteries is impaired, resulting in reduced perfusion, increased oxidative stress and inflammation.[@R12]

Although there are yet no validated biomarkers that allow to identify women at risk for pre-eclampsia, levels of angiogenic and antiangiogenic factors are altered in women with pre-eclampsia. Levels of sFlt-1 are elevated and levels of PlGF are decreased, even before clinical symptoms of disease were overt.[@R13]The ratio of sFlt-1/PlGF is a promising set of biochemical markers for prediction of pre-eclampsia. There is a pathogenic difference between early pre-eclampsia (onset of disease before 32--34 weeks of pregnancy) and late pre-eclampsia (onset of disease after 32--34 weeks of pregnancy). Early pre-eclampsia is characterised by a significant placental dysfunction, leading to a high risk of intrauterine growth restriction. In late pre-eclampsia there is more evidence of pre-existing maternal inflammation and/or cardiovascular maladaptation.[@R7] The distinction is not always that clear, and is under debate.

Cystatin C, a protease inhibitor, is also increased in pre-eclamptic women. Cystatin C can be used as an endogenous marker for renal function, synthesised by all nucleated cells, at a constant rate and exclusively eliminated by glomerular filtration.[@R16] Saleh *et al* found that levels of cystatin C were significantly higher in the second trimester of pregnancy in women who developed pre-eclampsia.[@R17] Angiogenesis-related and stress-related pathways may underlie the vascular effects of PM~2.5~ exposure during pregnancy.[@R10] Endothelin-1 is an established biomarker of endothelium dysfunction.[@R20] Nuclear factor of activated T cells (NFAT) contributes to diverse functions and was identified as a critical component of VEGF-induced angiogenesis.[@R21]

Higher exposure to PM~2.5~ and O~3~ during the first trimester are associated with pre-eclampsia, gestational hypertension and preterm delivery.[@R22]

We hypothesise that exposure to PM~2.5~ in the first trimester of pregnancy interferes with the maternal vascular remodelling process and that impaired remodelling between 9 weeks and 18 weeks results in reduced placental perfusion and oxidative stress.[@R23]

In 2011 WHO stated in a report that supplementation of calcium during pregnancy for women at high risk of developing pre-eclampsia is recommended.[@R6] They also state that low-dose acetylsalicylic acid (75 mg/day) is recommended in the same population. A recent study by Souza *et al*[@R24] confirmed that supplementation with 100 mg aspirin plus 2 g calcium when started after 20 weeks of gestational age reduced the rate of superimposed pre-eclampsia and intrauterine growth restriction in women with chronic hypertension and abnormal second-trimester uterine artery Doppler.[@R24] If this study can predict which women are at risk for hypertensive disorders during pregnancy or pre-eclampsia, supplementation of aspirin and calcium can be started in order to reduce perinatal risks.

Objectives and aims of the IPANEMA Study {#s1a}
----------------------------------------

This study aims to evaluate the effects of exposure to PM and outdoor air pollutants on the clinical pregnancy outcome for mother and child and to determine which biochemical changes in maternal, placental and cord blood best explain this effect.Objective 1: Correlate estimated personal PM~2.5~ exposures to angiogenesis-related markers for hypertensive disorders in pregnant woman.Objective 2: Gain more insight in the pathophysiology behind cardiovascular effects of air pollution during pregnancy, plausible underlying molecular pathways will be assessed, for example, stress-related and angiogenesis-related pathways.

Methods and analysis {#s2}
====================

Study design and setting {#s2a}
------------------------

The IPANEMA Study is a regional prospective cohort study, recruiting pregnant women in the Antwerp region in Belgium.

Data are collected during pregnancy and at delivery, as well as immediately postpartum. Blood samples, hair samples and anthropometric measurements are obtained. Self-administered questionnaires are completed at different time frames in pregnancy, in relation to sample taking (see [figure 1](#F1){ref-type="fig"}).

![Visits and interventions during the IPANEMA Study.](bmjopen-2017-020028f01){#F1}

Study sample {#s2b}
------------

### Study cohort {#s2b1}

Pregnant women are recruited within the network of Antwerp University. The leading centre will be University Hospital Antwerp, a tertiary centre with a maternal intensive care unit and a neonatal intensive care unit and 1000 deliveries a year.

The aim is to enrol 200 pregnant women over a 3 -year recruitment period. An increase of 2% of pregnant women who develop pre-eclampsia or hypertensive disorders can be considered clinically relevant.

Diagnosis of pre-eclampsia (onset of a new episode of hypertension during pregnancy (with persistent diastolic blood pressure \>90 mm Hg) with the occurrence of substantial proteinuria (\>0.3 g/24 hours)) and hypertensive disorders are made using WHO guidelines.[@R6]

### Eligibility criteria {#s2b2}

The inclusion criteria are (see [figure 2](#F2){ref-type="fig"})A singleton pregnancyMore than 12 weeks of gestational ageDelivery planned in a hospital within the network of Antwerp UniversityDutch speaking

The exclusion criteria are:Multiple pregnancyPlanned home delivery or planned delivery in another hospital

![Eligibility criteria.](bmjopen-2017-020028f02){#F2}

### Power calculation and statistical analyses {#s2b3}

The incidence of pre-eclampsia in pregnancy is approximately 5%. An increase of 2% is of interest. A doubling in incidence is therefore clinically relevant. With a sample size of 200 subjects, a doubling from 5% to 10% can be detected with 80% power and 5% significance level.

Data analysis will be done using SPSS V.24.0.

Recruitment started in the summer of 2015 and we aim to collect all participants by the end of 2018.

Study visits {#s2c}
------------

Women are recruited by the midwife or obstetrician at 12 weeks of gestational age, typically at the second routine antenatal visit.

Signed informed consent for participating in the study is obtained before the start.

### Blood collections (maternal and umbilical cord) {#s2c1}

Venous blood is drawn around 24 weeks of gestational age ([table 1](#T1){ref-type="table"}).

###### 

Tests on maternal blood sample

  ------------------------------------------ --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Routine blood sampling (UZA)               Urea, creatinin, CRP, LDH, AST, ALT, uric acid, APTT, PT, fibrinogen, D-dimers, glucose, erythrocytes/haematocrit, haemoglobin, thrombocytes, leucocytes, ferritin, toxoplasmosa (IgG and IgM),\
                                             Cytomegalovirus (IgG and IgM), herpes simplex IgG, Varicella zoster IgG, rubella IgG, parvovirus (IgG and IgM), Syphilis (RPR and TPHA), Indirect Coomb's test

  Biomarkers of pre-eclampsia                sFlt-1, PlGF, cystatin C, endothelin

  Molecular pathway and transcript markers   m(i)RNA expression, telomere length, DNA methylation
  ------------------------------------------ --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ALT, alanine transaminase; APTT, activated partial thromboplastin time; AST, aspartate aminotransferase; CRP, C-reactive protein; LDH, lactate dehydrogenase; PlGF, placental growth factor; PT, prothrombin time; RPR, rapid plasma reagin; sFlt-1, soluble fms-like tyrosine kinase 1; TPHA, Treponema pallidum haemagglutination; UZA, University Hospital Antwerp.

Umbilical cord blood is taken at the time of birth ([table 2](#T2){ref-type="table"}).

###### 

Tests on umbilical blood sample

  -------------------- ------------------------------------------------------
  Transcript markers   m(i)RNA expression, telomere length, DNA methylation
  -------------------- ------------------------------------------------------

*Measurement of molecular pathway and transcript markers* For analysis of the m(i)RNA profile, whole blood is collected in Tempus Blood RNA tubes (Applied Biosystems) and stored at −80°C until analysis. Telomere length and DNA methylation will be assessed on blood samples collected in EDTA tubes, which are stored at −80°C.

In order to gain more insight into pathophysiological pathways, relevant biomarkers and transcript markers will be analysed. Specific transcript markers will be selected that were previously associated with exposure to PM, intrauterine growth retardation or stress-induced and angiogenesis pathways, for example, glucocorticoid receptor signalling pathway, NFAT signalling pathway, and so on.[@R25]

### Urine collections {#s2c2}

Urine samples are taken by the pregnant women themselves, after a minimum of 8 hours fasting (morning urine). Samples are handed to the midwife at the antenatal visit, and placed in a freezer at −20°C within 12 hours of collection. Analysis will be performed at the Flemish Institute for Technological Research.

Two urine samples are collected at 20 weeks and at 30 weeks gestational age; 8-oxo-deoxyguanosine will be determined in the samples.

### Hair collections {#s2c3}

Being incorporated into the growing hair, hair cortisol concentrations (HCCs) provide a retrospective reflection of integrated cortisol secretion over periods of several months.[@R26]

Hair samples are drawn by the midwife around 24 weeks of gestational age and 3 days after delivery. Long periods of stress are associated with increased HCCs.[@R26] Confounding variables are low maternal education, season of delivery, smoking during pregnancy and obesity.[@R27] Titanium scissors are cleaned with denaturated ethanol and the midwife wears disposable gloves in order to limit contamination. A lock of hair with a thickness of a match (2 mm) and a length of 4 cm will be taken and put in an envelope. Analysis will be performed at the University of Southern Denmark.

### Statistical analysis {#s2c4}

Regression models will be calculated. In particular, birth weight will be correlated with PM~2.5~ values using linear regression, pre-eclampsia with blood pressure evolution and PM~2.5~ using logistic regression, birth weight, birth weight (dichotomised) and pre-eclampsia with sFlt-1, PlGF, cystatin C and PM~2.5~ using linear and logistic regressions, respectively, and birth weight (dichotomised) versus inflammatory parameters using logistic regression. The effect of the following a priori covariates will be analysed: history of pre-eclampsia, diabetes, BMI at start, age, smoking, intake of low dose aspirin and pre-existing hypertension. These factors will however not be a reason for exclusion.

### Questionnaires {#s2c5}

There are four different questionnaires:Questionnaire on general habits, socioeconomic factors, lifestyle and eating habitsWe use a self-designed questionnaire to extensively collect information on ethnic origin and education level, on employment, income and work environment, on family history of diseases and chronic disorders, on eating habits, on previous pregnancies and other habits (smoking, alcohol consumption).Questionnaire on lifestyle during previous 3 daysWe use a self-designed questionnaire to extensively collect information on contact with possible toxic factors and on eating pattern of the previous 3 days.Questionnaire on residential factsWe use a self-designed questionnaire to collect information about the exact location of the bedroom window and other possible factors influencing concentrations of PM.Questionnaire on stress factors and birth factsWe use a self-designed questionnaire to extensively collect information on stress levels during pregnancy, on birth facts and on medication during pregnancy.

Questionnaires will be taken at different visits ([table 3](#T3){ref-type="table"})

###### 

Questionnaires

                                                                                        \<12 weeks    20 weeks         30 weeks                    birth
  ------------------------------------------------------------------------------------- ------------- ---------------- --------------------------- --------------------
  Questionnaire on general habits, socioeconomic factors, lifestyle and eating habits   Recruitment                                                
  Questionnaire on lifestyle during previous 3 days                                                   Urine sample 1   Urine sample 2              
  Questionnaire on residential facts                                                                                   4--8 weeks prior to visit   
  Questionnaire on stress factors and birth facts                                                                                                  3 days after birth

Additional clinical information and data about medication will be obtained by detailed data extraction from the hospital records.

Outcomes of the study {#s2d}
---------------------

### Diagnosis of cardiovascular disorders {#s2d1}

Pre-eclampsia is defined as the onset of a new episode of hypertension during pregnancy (with persistent diastolic blood pressure \>90 mm Hg) with the occurrence of substantial proteinuria (\>0.3 g/24 hours).

### Pregnancy and delivery outcome data {#s2d2}

*Maternal data* that are prospectively collected are: pregnancy duration, pre-eclampsia, hypertensive disorders.

*Delivery data* are: type of labour, type of delivery.

*Neonatal data* are: birth weight, preterm delivery, Apgar Scores at 1 min, 5 min and 10 min, congenital anomalies, and so on.

### Other study measurements {#s2d3}

#### Measurement of sFlt-1, PlGF and cystatin C {#s2d3a}

Blood samples taken at the study visit around 24 weeks of gestational age for the analyses of sFlt-1, PlGF and cystatin C are collected, processed and aliquoted within 24 hours of collection. The serum samples are stored at −80°C until analysis at Algemeen Medisch Laboratorium. sFlt-1 and PlGF will be determined using an electrochemiluminescence-based sandwich immunoassay on Cobas e 411 (Roche Diagnostics, Mannheim, Germany).[@R28] Cystatin C will be determined using a particle-enhanced immunonephelometric assay (N Latex cystatin C, Siemens Healthcare Diagnostics, Marburg, Germany) by use of a BN II nephelometer (Siemens Healthcare Diagnostics). This assay has a calibration traceable to the first certified reference material for cystatin C in human serum (ERM-DA471/IFCC).[@R30]

Discussion {#s3}
==========

IPANEMA is the first prospective study to assess the impact of PM on mothers and babies in Antwerp, Belgium.

Exposure to PM is debated on the political scene but robust data showing a relationship with hypertensive disorders of pregnancy are difficult to find. In Antwerp the design of a safe and functional tunnel for the highway is now focus of public discussion. Following the Barcelona experience a group of people want an urban tunnel complex to lower the amount of PM.

IPANEMA would like to create robust data on the correct impact of air pollution, in particular on pregnant women, a vulnerable population. IPANEMA uses prospective data from the beginning of the pregnancy till childbirth.

Available studies have been highly biased, probably in favour of detecting an effect even if this is minimal, by their retrospective nature (missing for example, women who left the area before giving birth), not correcting for socioeconomic or ethic influences, using very raw and approximate models managing up to several square kilometres as identical areas of pollution, not compensating for time spent in traffic, at work or in other regions during weekends and holidays. Furthermore the discussion on the impact of air pollution had been partially taken over by politics, without robust data. Data from IPANEMA will help to estimate the real individual dose-effect relation for pregnant women.
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